NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 5 of 24
Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis
NCT06984523
Multi-Center Project: Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure
NCT06457152
Adaption of the STAIR-NT Trauma Intervention for Polysubstance Populations
NCT06307340
Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk
NCT05828849
Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery
NCT06477133
Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia
NCT06128356
Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)
NCT06311045
Hearing Program in Primary Care
NCT05943509
Prenatal Starting Early Program mHealth
NCT06087133
Permanent Supportive Housing Overdose Prevention
NCT05786222
Split Chest Breast Neurotization
NCT05757778
Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment
NCT05601583
Community Mobilization for Improved Clean Cookstove Uptake, Household Air Pollution Reduction, and Hypertension Prevention
NCT05048147
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NCT05678322
Platelets in Pregnancy
NCT06194643
BRInging the Diabetes Prevention Program to GEriatric Populations
NCT05166785
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
NCT05621759
Stimulating the Cochlear Apex Without Longer Electrodes
NCT06901674
Understanding Poor Vaccine Responses to Hepatitis B Vaccination
NCT04674462
Life Study: Lifestyle Intervention in Fibroid Elimination
NCT05416424
ED Observation for Opioid Use Disorder
NCT05064826
Understanding the Long-term Impact of COVID on Children and Families
NCT05172011
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI
NCT05615415
Goal-directed CPR Using Cerebral Oximetry
NCT04924985
Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
NCT05037123
Personalized Dietary Management in Type 2 Diabetes
NCT05046886
Autonomic Modulation in Takotsubo Syndrome
NCT03324529
Integration of Hypertension Management Into HIV Care in Nigeria
NCT04704336
Black Church Treatment Study
NCT04580810
Exercise for Anxiety
NCT04638946
Napoleon Measurement of Gastrojejunal Anastomosis
NCT04832282
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
NCT04464980
Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
NCT04784416
Female Asian Nonsmoker Screening Study
NCT05164757
Optimal Dosing of IC-Green for Visualization of Rotator Cuff Vascularity Using Advanced Imaging Modality Arthroscopy
NCT04340752
Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy
NCT03768492
Postoperative Immobilization and Physical Therapy Following Volar Locked Plating for Distal Radius Fractures
NCT04324580
Human Epilepsy Project 3
NCT05374928
Families, Children and Teachers Thriving Together
NCT04276363
Diffusion MRI for Head and Neck Cancer
NCT04251481
Pediatric Parenting Support in Flint
NCT03945552
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT03999749
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NCT03971461
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
NCT04009148
Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)
NCT03927768
Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT03400215
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
NCT03537586
Sleep Aging and Risk for Alzheimer's 2.0
NCT03278119
Acoustic Stimulation for Seizure Suppression
NCT03198494
Heart Attack Research Program- Imaging Study
NCT02905357
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.